Repository logo
Log in(current)
Repository logoMIT Open ScholarshipDSpace@MIT
  1. Home
  2. MIT Open Access Articles
  3. MIT Open Access Articles
  4. STING agonist delivery by tumour-penetrating PEG-lipid nanodiscs primes robust anticancer immunity

STING agonist delivery by tumour-penetrating PEG-lipid nanodiscs primes robust anticancer immunity

Thumbnail Image
Download
Name

s41563-022-01251-z.pdf

Description
Published version
Size

16.71 MB

Format

Adobe PDF

Checksum (MD5)

74fd28652b657f96d0fa831da5c83eec

sword-2023-02-01T18:16:10.original.xml (130 B)
Original SWORD entry document
Author(s)
Dane, Eric L
•
Belessiotis-Richards, Alexis
•
Backlund, Coralie
•
Wang, Jianing
•
Hidaka, Kousuke
•
Milling, Lauren E
•
Bhagchandani, Sachin
•
Melo, Mariane B
•
Wu, Shengwei
•
Li, Na
more
Date Issued
2022
Journal
Nature Materials
Publisher
Springer Science and Business Media LLC
Citation
Dane, Eric L, Belessiotis-Richards, Alexis, Backlund, Coralie, Wang, Jianing, Hidaka, Kousuke et al. 2022. "STING agonist delivery by tumour-penetrating PEG-lipid nanodiscs primes robust anticancer immunity." Nature Materials, 21 (6).
Version
Final published version
Abstract
AbstractActivation of the innate immune STimulator of INterferon Genes (STING) pathway potentiates antitumour immunity, but systemic delivery of STING agonists to tumours is challenging. We conjugated STING-activating cyclic dinucleotides (CDNs) to PEGylated lipids (CDN-PEG-lipids; PEG, polyethylene glycol) via a cleavable linker and incorporated them into lipid nanodiscs (LNDs), which are discoid nanoparticles formed by self-assembly. Compared to state-of-the-art liposomes, intravenously administered LNDs carrying CDN-PEG-lipid (LND-CDNs) exhibited more efficient penetration of tumours, exposing the majority of tumour cells to STING agonist. A single dose of LND-CDNs induced rejection of established tumours, coincident with immune memory against tumour rechallenge. Although CDNs were not directly tumoricidal, LND-CDN uptake by cancer cells correlated with robust T-cell activation by promoting CDN and tumour antigen co-localization in dendritic cells. LNDs thus appear promising as a vehicle for robust delivery of compounds throughout solid tumours, which can be exploited for enhanced immunotherapy.
MIT Department
Koch Institute for Integrative Cancer Research at MIT
Massachusetts Institute of Technology. Department of Biological Engineering
Massachusetts Institute of Technology. Department of Chemical Engineering
Massachusetts Institute of Technology. Department of Materials Science and Engineering
Ragon Institute of MGH, MIT and Harvard
Terms of Use
Creative Commons Attribution 4.0 International license
https://creativecommons.org/licenses/by/4.0/
Persistent DSpace Link
https://hdl.handle.net/1721.1/147842
DOI of Published Version
https://doi.org/10.1038/S41563-022-01251-Z
Repository logo
PrivacyPermissionsAccessibilityContact us
Repository logo
Notify us about copyright concerns.